Open Orphan PLC New GBP2.5m Influenza Challenge Study Contract Win (3129E)
November 05 2020 - 1:00AM
UK Regulatory
TIDMORPH
RNS Number : 3129E
Open Orphan PLC
05 November 2020
5 November 2020
Open Orphan plc
("Open Orphan" or the "Company")
New GBP2.5m Influenza Challenge Study Contract Win
Open Orphan plc (ORPH), a rapidly growing specialist CRO
pharmaceutical services company which is the world leader in the
testing of vaccines and antivirals using human challenge clinical
trials is pleased to announce the signing of a GBP2.5 million
contract by hVIVO, a subsidiary of Open Orphan, to conduct an
Influenza human challenge study with a US biotechnology
company.
The study is expected to commence at hVIVO's 24-bedroom
quarantine clinic in East London in H2 2021 and to be fully
completed by year end 2021, generating GBP2.5m of revenue. This
contract builds on the Company's recent challenge study contract
wins in RSV and COVID-19 and demonstrates the breadth of Open
Orphan's service offering and the expertise within the Group as a
world leader in its field.
For this study, Venn Life Science 's Paris team will complete
the biometrics, demonstrating how the various parts of the Open
Orphan plc Group can work together to deliver high-quality services
to clients. Venn's Paris team are highly regarded in the field as
one of the leading providers in this area which is a perfect
complement to the London offering.
Cathal Friel, Executive Chairman, Open Orphan, said:
"We are delighted to be conducting this influenza challenge
study, recent events have highlighted the importance of treatments
for viral infections such as influenza and we are seeing an
increased level of interest amongst both pharma and biotech in
developing innovative new vaccines, antivirals, and
therapeutics.
The Company is pleased to be continuing to deliver on our
pipeline of opportunities. This has been due to the exceptional
work from the hVIVO team, building on the Company's long history as
the world leading challenge study provider. Both the team and I are
excited to see the progress being made by the Group and look
forward to continuing the momentum as we rapidly grow the business
to maximise shareholder value."
Interested in becoming a volunteer?
hVIVO recruits many of its volunteers for its challenge study
clinical trials through its dedicated volunteer recruitment
website, www.flucamp.com . hVIVO welcomes volunteers to take part
in our clinical trials under expertly supervised conditions, to
further medical research, and help us to take the understanding of
respiratory illnesses to a new level. Volunteers are central to the
work that we do; our studies focus on testing new treatments on
real people, in a safe, controlled, clinical environment.
Further details on all aspects of our volunteer programs
including testimonials from previous volunteers can be found at
www.flucamp.com .
If you are interested in being contacted and provided with
details about future COVID-19 human challenge study research,
please leave your contact details at www.UKCovidChallenge.com .
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the
publication of this announcement via a Regulatory Information
Service, this inside information is now considered to be in the
public domain.
For further information please contact
Open Orphan plc +353 (0)1 644 0007
Cathal Friel, Executive Chairman
Arden Partners plc (Nominated Adviser and +44 (0)20 7614
Joint Broker) 5900
John Llewellyn-Lloyd / Benjamin Cryer /
Dan Gee-Summons
+44 (0) 20 7220
finnCap plc (Joint Broker) 500
Geoff Nash / James Thompson/ Richard Chambers
Davy (Euronext Growth Adviser and Joint
Broker) +353 (0)1 679 6363
Anthony Farrell
+44 (0)20 3757
Camarco (Financial PR) 4980
Tom Huddart / Hugo Liddy
Notes to Editors - Open Orphan:
Open Orphan is a rapidly growing niche CRO pharmaceutical
services company which is the world leader in the testing of
vaccines and antivirals through the use of human challenge clinical
trials. Conducted from Europe's only 24-bedroom quarantine clinic
with onsite virology providing individually isolated rooms and
connected to our specialist laboratory facility. hVIVO's challenge
studies require healthy volunteers to take part, volunteers are
recruited through FluCamp, learn more at www.FluCamp.com . The
hVIVO facility offers highly specialised virology and immunology
laboratory services to support pre-clinical and clinical
respiratory drug, antiviral, and vaccine discovery and development.
Reliable laboratory analysis underpinned by scientific expertise is
essential when processing and analysing clinical samples. Robust
quality processes support our team of scientists in the delivery of
submission ready data.
The Company has a leading portfolio of 8 viral challenge study
models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough and 1 COPD
viral challenge models. As announced in early March, Open Orphan is
rapidly advancing a number of Coronavirus challenge study models
and expects to be helping many COVID-19 vaccine development
companies to test their vaccines. No other company in the world has
such a portfolio, with only two competitors globally having 1
challenge study model each. hVIVO also works with companies in the
UK and Ireland to provide COVID-19 testing to staff to protect
staff and customers from a workplace COVID-19 outbreak through its
COVID Clear offering.
Open Orphan comprises of two commercial specialist CRO services
businesses, hVIVO and Venn Life Sciences and is also building out a
valuable data platform business. hVIVO has built up one of the
world's largest databases of infectious disease progression data
and we are populating our Open Orphan Health Data platform with
this historical hVIVO data. In our clinical trials going forward,
we are also planning to collect data on volunteer's via wearables
during clinical trials. Therefore, Open Orphan's data, which may
yield valuable digital biomarkers, could be one of the more
sought-after datasets by many of the large wearables /smart watch
wearables providers around the world. In June 2019, Open Orphan
acquired AIM-listed Venn Life Sciences Holdings plc in a reverse
take-over and in January 2020 it completed the merger with hVIVO
plc in January 2020. Venn is an integrated drug development
consultancy firm which offers CMC (chemistry, manufacturing and
controls), preclinical, Phase I & II clinical trials design and
execution. The merger with hVIVO created a European full pharma
services company broadening the Company's customer base and with
complementary specialist CRO services, widened the range of the
Company's service offerings.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTFSLEELESSESF
(END) Dow Jones Newswires
November 05, 2020 02:00 ET (07:00 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Apr 2024 to May 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From May 2023 to May 2024